{"id":"NCT02667587","sponsor":"Bristol-Myers Squibb","briefTitle":"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","officialTitle":"A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-09","primaryCompletion":"2020-12-22","completion":"2024-04-09","firstPosted":"2016-01-29","resultsPosted":"2022-02-03","lastUpdate":"2025-06-18"},"enrollment":716,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Brain Neoplasms"],"interventions":[{"type":"DRUG","name":"Nivolumab","otherNames":["Opdivo","Nivo","N","BMS-936558"]},{"type":"DRUG","name":"Temozolomide","otherNames":["Temodar","TMZ","Temodal","Temcad"]},{"type":"RADIATION","name":"Radiotherapy","otherNames":["RT"]},{"type":"OTHER","name":"Nivolumab Placebo","otherNames":[]}],"arms":[{"label":"Nivolumab + Temozolomide + Radiotherapy","type":"EXPERIMENTAL"},{"label":"Nivolumab placebo + Temozolomide + Radiotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving nivolumab in addition to temozolomide plus radiation therapy.","primaryOutcome":{"measure":"Progression-free Survival (PFS) Determined by BICR","timeFrame":"From randomization to the date of the first documented tumor progression or death by any cause. (up to approximately 4.5 years)","effectByArm":[{"arm":"Radiotherapy, Temozolomide Plus Nivolumab","deltaMin":10.64,"sd":null},{"arm":"Radiotherapy, Temozolomide Plus Placebo","deltaMin":10.32,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":123,"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","Norway","Poland","Russia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["35511454","32691060"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm","https://www.bmsstudyconnect.com/s/US/English/USenHome"]},"adverseEventsSummary":{"seriousAny":{"events":259,"n":355},"commonTop":["Fatigue","Nausea","Constipation","Headache","Alopecia"]}}